Document Detail

Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in belgium.
MedLine Citation:
PMID:  22452528     Owner:  NLM     Status:  In-Data-Review    
Objectives: Lacosamide is an anti-epileptic drug, indicated as adjunctive therapy for patients with focal seizures with or without secondary generalization. This study aims to assess the cost effectiveness of standard anti-epileptic drug therapy plus lacosamide 300 mg/day compared with standard therapy alone from the perspective of the Belgian healthcare payer. Methods: The treatment pathway of a hypothetical cohort of 1000 patients over 2 years was simulated using a decision tree. Data about health state probabilities, seizure frequency and utility values were taken from lacosamide trials or from the literature. Effectiveness measures included the number of seizures avoided and the number of quality-adjusted life-years gained. Unit costs were taken from national references. Resource use was estimated by a panel of eight neurologists with extensive experience in epilepsy. The price year was 2008. Deterministic and probabilistic sensitivity analyses were conducted. Results: Over a 24-month period, standard anti-epileptic drug therapy plus lacosamide led to a reduction of seven seizures, an increase of 0.038 quality-adjusted life-years and a cost decrease of &U20AC;3619 per patient compared with standard therapy alone. Using a willingness to pay of &U20AC;30 000 per quality-adjusted life-year, the net monetary benefit of standard anti-epileptic drug therapy plus lacosamide amounted to &U20AC;4754. The probability of standard anti-epileptic drug therapy plus lacosamide being cost effective was 97.3%, 99.8%, 99.9% and 100% at 6, 12 , 18 and 24 months, respectively. Conclusion: In patients with difficult-to-treat epilepsy, standard anti-epileptic drug therapy plus lacosamide appears to be a cost-effective option in Belgium.
Steven Simoens; Liesbet De Naeyer; Peter Dedeken
Related Documents :
22466618 - Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic c...
6549128 - The role of txa2 in hypertension.
6103968 - Evaluation of a new antihypertensive agent. minoxidil.
22794308 - Impact of physical incompatibility on drug mass flow rates: example of furosemide-midaz...
2082908 - Hyperlipidaemia and hypertension.
3617438 - Environmental considerations for minor use animal drugs.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  CNS drugs     Volume:  26     ISSN:  1172-7047     ISO Abbreviation:  CNS Drugs     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9431220     Medline TA:  CNS Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  337-50     Citation Subset:  IM    
KU Leuven, Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacological revascularization of acute ischaemic stroke: focus on challenges and novel strategie...
Next Document:  Ziprasidone and the Corrected QT Interval: A Comprehensive Summary of Clinical Data.